BioPorto Diagnostics A/S

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Companys tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Companys flagship products are based on the NGAL biomarker and designed to...

Antibodies,acute kidney injury (aki) biomarker,in-vitro diagnostics (ivd),assay development,complement and innate immunity,appetite regulating hormones,ngal biomarker,diagnostics,generic rapid assay device (grad),lateral flow assay development (grad),clinical research,drug induced kidney injury (diki),fda qualified biomarker (bqp),scientific and pre-clinical drug research,pre-clinical,non-clinical research,clinical research,ngal elisa kits (human and animal,and research & development

Bioporto diagnostics a/s operates in the Biotechnology research industry.

Bioporto diagnostics a/s's revenue is 11m - 100m

Bioporto diagnostics a/s has 11 - 50 employees.